株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

OncoMed Pharmaceuticals, Inc.:製品パイプライン分析

OncoMed Pharmaceuticals, Inc. - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 251699
出版日 ページ情報 英文 64 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
OncoMed Pharmaceuticals, Inc.:製品パイプライン分析 OncoMed Pharmaceuticals, Inc. - Product Pipeline Review - 2016
出版日: 2016年08月24日 ページ情報: 英文 64 Pages
概要

OncoMed Pharmaceuticals, Inc. は、治療用モノクローナル抗体の開発をしているバイオテクノロジー企業です。同社はまた標的を定めた抗体や、他のタンパク質ベースの治療薬の開発も行っており、それらは癌の幹細胞を標的として変調させ、成長を抑制するよう設計されています。

当レポートでは、OncoMed Pharmaceuticals, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

OncoMed Pharmaceuticals, Inc.の基本情報

  • OncoMed Pharmaceuticals, Inc.の概要
  • 主要情報
  • 企業情報

OncoMed Pharmaceuticals, Inc.:R&Dの概要

  • 主な治療範囲

OncoMed Pharmaceuticals, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

OncoMed Pharmaceuticals, Inc.:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品 IND/CTA に申請された製品/併用療法モダリティ
    • 前臨床段階にある製品/併用療法モダリティ

OncoMed Pharmaceuticals, Inc.:薬剤プロファイル

  • demcizumab
  • tarextumab
  • ipafricept
  • OMP-52M51
  • vantictumab
  • OMP-305B83
  • Biologic for Cancer
  • Biologic to Inhibit Wnt Pathway for Cancer
  • Monoclonal Antibody to Inhibit Other Pathways for Cancer
  • OMP-131R10
  • Small Molecules for Oncology

OncoMed Pharmaceuticals, Inc.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

OncoMed Pharmaceuticals, Inc.:最近のパイプライン動向

OncoMed Pharmaceuticals, Inc.:休止中のプロジェクト

OncoMed Pharmaceuticals, Inc.:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08129CDB

Summary

Global Markets Direct's, 'OncoMed Pharmaceuticals, Inc. - Product Pipeline Review - 2016', provides an overview of the OncoMed Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by OncoMed Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of OncoMed Pharmaceuticals, Inc.
  • The report provides overview of OncoMed Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses OncoMed Pharmaceuticals, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features OncoMed Pharmaceuticals, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate OncoMed Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for OncoMed Pharmaceuticals, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding OncoMed Pharmaceuticals, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • OncoMed Pharmaceuticals, Inc. Snapshot
    • OncoMed Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • OncoMed Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • OncoMed Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • OncoMed Pharmaceuticals, Inc. - Pipeline Products Glance
    • OncoMed Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • OncoMed Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • OncoMed Pharmaceuticals, Inc. - Drug Profiles
    • demcizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tarextumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • brontictuzumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ipafricept
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OMP-131R10
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OMP-305B83
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vantictumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IO-2
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IO-3
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Agonize GITR for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Hippo Pathway for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • OncoMed Pharmaceuticals, Inc. - Pipeline Analysis
    • OncoMed Pharmaceuticals, Inc. - Pipeline Products by Target
    • OncoMed Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • OncoMed Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • OncoMed Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • OncoMed Pharmaceuticals, Inc. - Recent Pipeline Updates
  • OncoMed Pharmaceuticals, Inc. - Dormant Projects
  • OncoMed Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • brontictuzumab
      • tarextumab
  • OncoMed Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • OncoMed Pharmaceuticals, Inc., Key Information
  • OncoMed Pharmaceuticals, Inc., Key Facts
  • OncoMed Pharmaceuticals, Inc. - Pipeline by Indication, 2016
  • OncoMed Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • OncoMed Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • OncoMed Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016
  • OncoMed Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • OncoMed Pharmaceuticals, Inc. - Phase II, 2016
  • OncoMed Pharmaceuticals, Inc. - Phase I, 2016
  • OncoMed Pharmaceuticals, Inc. - Preclinical, 2016
  • OncoMed Pharmaceuticals, Inc. - Pipeline by Target, 2016
  • OncoMed Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • OncoMed Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • OncoMed Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
  • OncoMed Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016
  • OncoMed Pharmaceuticals, Inc. - Dormant Developmental Projects,2016
  • OncoMed Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016

List of Figures

  • OncoMed Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016
  • OncoMed Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • OncoMed Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • OncoMed Pharmaceuticals, Inc. - Pipeline by Target, 2016
  • OncoMed Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • OncoMed Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • OncoMed Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
Back to Top